You have successfully logged out.

Hello !
Logout
close

No content results match your keyword.

Content

    No product results match your keyword.

    Products

      SeQuent® DCBs

      The proven performers in coronary angioplasty

      Backing up cardiologists with unparalleled clinical data and proven performance for both paclitaxel and sirolimus coated balloons.

      Cooporation

      Cardiovascular News

      Dr. Marie-Claude Morice, Institute Hospitalier Jacques Cartier, Massy, France

      Global Experts

      Learning curve with DCB

      Drug Coated Balloon Online Trainings


      Want to learn more about DCBs and the importance of lesion preparation in PCI? Register here for exclusive access to recordings of our Drug Coated Balloon online training courses.

      Register now

      Paclitaxel and sirolimus coated balloons

      SeQuent® DCBs – The choice is yours.

      SeQuent® Please NEO – Paclitaxel coated balloon

      B. Braun´s paclitaxel coated balloon SeQuent® Please NEO is the best investigated DCB [1] in the field of percutaneous coronary interventions (PCI). It has demonstrated its convincing performance, efficacy and safety in more than 110 published studies (including more than 35 RCTs) – with over 25,000 documented patients, conducted in more than 20 countries. 

      Chart of THINK ABOUT… Best investigated DCB SeQuent® Please/Neo
      SeQuent® Please NEO for coronary angioplasty

      Clinical evidence

      Publications for SeQuent® Please / NEO

      The coronary DCB has been investigated in more than 110 studies with over 25,000 documented patients, conducted in more than 20 countries.

      All clinical trials at a glance as PDF download

      Study summaries SeQuent® Please / NEO

      Randomized controlled trials

      Not randomized controlled trials & observational studies

      SeQuent® SCB – Sirolimus coated balloon
      SeQuent® SCB – Sirolimus coated balloon

      Clinical evidence SeQuent® SCB

      Preclinical work and randomized controlled trials

      Treatment methodology

      According to Consensus Group recommendations [6], [7]

      Lesion preparation

      Acceptable angiographic result

      • No dissection or only Type A or B
        No flow limiting dissection
      • TIMI III / FFR > 0.8
      • Residual stenosis ≤ 30 %
         

      Unacceptable angiographic result

      • Dissection Type C-F
        Flow limiting dissection
      • TIMI < III / FFR < 0.8
      • Residual stenosis > 30 %
         

      Lesion therapy

      DCB-only with with SeQuent® Please NEO or SeQuent® SCB

      • De-Novo
      • ISR
         

      Stenting

      • DES implantation with Coroflex® ISAR NEO
          

      Related documents

      • SeQuent® Please NEO

        Clinically proven drug coated balloon catheter

        link

      • SeQuent® SCB

        Sirolimus coated balloon catheter for PTCA

        link

      • SeQuent® Please NEO – Go Implant-Free!

        Safe and effective alternative to DES in de novo lesions

        pdf, 27.8 KB

      • Cardiology Catalog

        Your partner for coronary angioplasty

        link

      [1] All numbers referring to clinical coronary trials on PCBs, patients enrolled therein and countries in which these trials were conducted, are based on a PubMed literature search conducted with due diligence in February/March 2022. (Data on file at B. Braun)

      [2] Ali RM et al J Am Coll Cardiol Intv 2019;12:558-66

      [3] Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.

      [4] Ahmad WAW et al. JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779

      [5] Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.

      [6] Kleber FX et al. Clin Res Cardiol. 2013 Nov;102(11):785-97.

      [7] Jeger RV et JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402.